Department of Internal Medicine, L. Sacco Hospital, University of Milan, Via GB Grassi, 20157, Milan, Italy.
Cardiovascular Imaging Unit, Department of Cardiology, L. Sacco Hospital, University of Milan, Milan, Italy.
Intern Emerg Med. 2021 Nov;16(8):2173-2180. doi: 10.1007/s11739-021-02733-9. Epub 2021 May 21.
Cardiac dysfunction, mainly assessed by biomarker alterations, has been described in COVID-19 infection. However, there are still areas of uncertainty regarding its effective role in disease evolution. Aim of this study was to evaluate early echocardiographic parameters in COVID pneumonia and their association with severity disease and prognosis.
An echocardiographic examination was performed within 72 h from admission in 64 consecutive patients hospitalized for COVID-19 pneumonia in our medium-intensity care unit, from March 30th to May 15th 2020. Six patients were excluded for inadequate acoustic window.
Fifty-eight consecutive patients were finally enrolled, with a median age of 58 years. Twenty-two (38%) were classifiable as severe COVID-19 disease. Eight out of 58 patients experienced adverse evolution (six died, two were admitted to ICU and received mechanical ventilation), all of them in the severe pneumonia group. Severe pneumonia patients showed higher troponin, IL-6 and D-Dimer values. No significant new onset alterations of left and right ventricular systolic function parameters were observed. Patients with severe pneumonia showed higher mean estimated systolic pulmonary artery pressure (sPAP) (30.7 ± 5.2 mmHg vs 26.2 ± 4.3 mmHg, p = 0.006), even if in the normality range values. No differences in echocardiographic parameters were retrieved in patients with adverse events with respect to those with favorable clinical course.
A mild sPAP increase in severe pneumonia patients with respect to those with milder disease was the only significant finding at early echocardiographic examination, without other signs of new onset major cardiac dysfunction. Future studies are needed to deepen the knowledge regarding minor cardiac functional perturbation in the evolution of a complex systemic disorder, in which the respiratory involvement appears as the main character, at least in non-ICU patients.
心脏功能障碍主要通过生物标志物改变评估,在 COVID-19 感染中已有描述。然而,其在疾病进展中的有效作用仍存在不确定性。本研究旨在评估 COVID 肺炎患者的早期超声心动图参数及其与疾病严重程度和预后的关系。
2020 年 3 月 30 日至 5 月 15 日,在我们的中强度护理病房连续收治 64 例 COVID-19 肺炎住院患者,在入院后 72 小时内行超声心动图检查。因声窗不足排除 6 例患者。
最终纳入 58 例连续患者,中位年龄 58 岁。22 例(38%)可归类为严重 COVID-19 疾病。58 例患者中有 8 例出现不良转归(6 例死亡,2 例转 ICU 行机械通气),均为重症肺炎组。重症肺炎患者的肌钙蛋白、IL-6 和 D-二聚体值较高。未见左、右心室收缩功能参数新发明显改变。重症肺炎患者的平均估计收缩肺动脉压(sPAP)较高(30.7±5.2mmHg 比 26.2±4.3mmHg,p=0.006),尽管仍处于正常范围。与预后良好的患者相比,发生不良事件的患者的超声心动图参数无差异。
与病情较轻的患者相比,重症肺炎患者的 sPAP 轻度升高是早期超声心动图检查中唯一的显著发现,无新发严重心脏功能障碍的其他迹象。需要进一步研究来加深对复杂全身性疾病(以呼吸受累为主要特征)演变中小的心脏功能障碍的认识,至少在非 ICU 患者中如此。